Literature DB >> 1293269

Salbutamol infusion to treat neonatal hyperkalaemia.

A Greenough1, E F Emery, R Brooker, H R Gamsu.   

Abstract

Salbutamol infusion, 4 micrograms/kg in 5 ml of water infused for 20 minutes, was given to treat hyperkalaemia (potassium level > 6.0 mmol/l) in 10 critically ill preterm infants (median gestational age 26 weeks). Seven infants had acute renal failure, two had persistent metabolic acidosis without renal failure and the remaining infant had a combination of acute renal failure and persistent metabolic acidosis. No infant developed a tachycardia or became hyperglycaemic in response to the infusion. Seven of the 10 infants ultimately died but this was at a mean of 9 days following the infusion and as a consequence of complications due to their extreme prematurity or major congenital abnormality. In response to the infusion the potassium level fell in 7 infants with acute renal failure by a median of 1.1 mmol/l (range 0.7-1.8) at one hour but in the three infants with a persistent metabolic acidosis, the potassium level continued to rise. We conclude that salbutamol infusion achieves, without side-effects, at least a temporary reduction in hyperkalaemia in preterm infants with renal failure, but not metabolic acidosis. Its effect is of sufficient duration to allow ample time for definitive therapy to be instituted and thus may be a useful alternative for infants in whom the possible hypoglycaemic side-effects of glucose and insulin should be avoided.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293269     DOI: 10.1515/jpme.1992.20.6.437

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

Review 1.  Interventions for non-oliguric hyperkalaemia in preterm neonates.

Authors:  Prakash Vemgal; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Acute renal failure in children: aetiology and management.

Authors:  G Filler
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.